# Rituximab + Immunotherapy in Follicular Lymphoma

> **NCT03636503** · PHASE1 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 24 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Utomilumab
- **DRUG:** Avelumab
- **DRUG:** PF04518600

## Key facts

- **NCT ID:** NCT03636503
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-30
- **Primary completion:** 2021-07-23
- **Final completion:** 2023-07-30
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Stopped was stopped prematurely due to drug manufacturer withdrawing supply/funding. Patients already enrolled on study were allowed to continue treatment.
- **Last updated:** 2025-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03636503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03636503, "Rituximab + Immunotherapy in Follicular Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03636503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*